Budzinski Introduces Legislation to Increase Competition and Lower Prescription Drug Costs
WASHINGTON, D.C. — Today, Congresswoman Nikki Budzinski (IL-13) introduced the Bringing Low-Cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act, which would discourage pharmaceutical companies from parking their exclusivity on a generic drug application. “Too many Americans are burdened by high drug prices, and Congress must act. Current policies are failing to foster competition and are hindering affordable options,” said Congresswoman Budzinski. “This bill aims to right this wrong by reducing exclusivity, enabling generics to enter the market sooner and lower prices for people.” Under current law, drug manufacturers are granted 180 days of market exclusivity when they are the first to file a generic drug application for a drug that does not yet have a generic. Unfortunately, some companies "park" or "hold" their exclusivity, blocking other companies from producing generics and keeping prices inflated. The BLOCKING
stLouIST